Lyra Therapeutics
Stock Forecast, Prediction & Price Target
Lyra Therapeutics Financial Estimates
Lyra Therapeutics Revenue Estimates
Lyra Therapeutics EBITDA Estimates
Lyra Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $285K N/A | $1.36M 378.24% | $1.55M 14.30% | Avg: $806.6K Low: $597.01K High: $1.00M avg. -48.22% | Avg: $10.06M Low: $4.59M High: $13.85M avg. 1147.83% | Avg: $34.26M Low: $15.64M High: $47.16M avg. 240.47% | Avg: $124.46M Low: $56.81M High: $171.32M avg. 263.21% |
Net Income
% change YoY
| $-42.41M N/A | $-55.27M -30.34% | $-62.68M -13.39% | Avg: $-86.43M Low: $-63.74M High: $-25.89M avg. -37.90% | Avg: $-94.11M Low: $-63.25M High: $-36.35M avg. -8.88% | Avg: $-67.23M Low: $-100.14M High: $-19.72M avg. 28.55% | Avg: $-21.16M Low: $-31.52M High: $-6.21M avg. 68.51% |
EBITDA
% change YoY
| $-43.61M N/A | $-53.67M -23.06% | $-65.25M -21.56% | Avg: $-161.31K Low: $-201.96K High: $-119.40K avg. 99.75% | Avg: $-2.01M Low: $-2.77M High: $-918.87K avg. -1147.83% | Avg: $-6.85M Low: $-9.43M High: $-3.12M avg. -240.47% | Avg: $-24.89M Low: $-34.26M High: $-11.36M avg. -263.21% |
EPS
% change YoY
| -$3.27 N/A | -$1.83 44.03% | -$1.26 31.14% | Avg: -$1.06 Low: -$1.28 High: -$0.52 avg. 16.19% | Avg: -$1.07 Low: -$1.27 High: -$0.73 avg. -1.64% | Avg: -$1.35 Low: -$2.01 High: -$0.4 avg. -25.77% | Avg: -$0.43 Low: -$0.63 High: -$0.12 avg. 68.51% |
Operating Expenses
% change YoY
| $43.9M N/A | $56.35M 28.36% | $68.67M 21.87% | Avg: $12.41M Low: $9.18M High: $15.54M avg. -81.92% | Avg: $154.91M Low: $70.71M High: $213.23M avg. 1147.83% | Avg: $527.44M Low: $240.76M High: $726.01M avg. 240.47% | Avg: $1.91B Low: $874.49M High: $2.63B avg. 263.21% |
FAQ
What is Lyra Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 12.57% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -63.74M, average is -86.43M and high is -25.89M.
What is Lyra Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 400.82% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $597.01K, average is $806.6K and high is $1.00M.
What is Lyra Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 14.32% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.28, average is -$1.06 and high is $-0.52.
What is the best performing analyst?
In the last twelve months analysts have been covering Lyra Therapeutics stock. The most successful analyst is Dennis Ding.